The Prime Minister continues to monitor the folder Aventis - Sanofi-Synthelabo. Although very taken by the elections, Jean-Pierre Raffarin took time Friday morning to receive the President of Aventis, Igor Landau, for almost an hour. During this visit, the two men discussed the hostile offer launched by Sanofi-Synthelabo on Franco-German pharmaceutical group. Igor Landau explained to the Prime Minister why he considers this "inappropriate" offer, particularly in terms of price, and he advocated a rapprochement with the Novartis Switzerland, according to a spokeswoman for Aventis. The Prime Minister he only listened to him, or continued to promote a solution negotiated between Sanofi-Synthelabo and Aventis March 16, Jean-Pierre Raffarin implicitly supported a reconciliation between the two French laboratories, "national interest", in highlighting the importance of vaccines in the fight against bioterrorism. A position that is always current, indicated Friday Matignon.
Despite this pressure, Aventis made the resistance. "We continue to work on a rapprochement with Novartis," indicates a close source from the folder. Daniel Vasella, President of the Swiss group, but said the week last to "Echoes" which he considered "very unlikely" that the group plays the White Knights, if the Government did not adopt a "neutral position". "". "We try to precisely find solutions on vaccines and employment, which will push the Government to change its mind, while creating value for the shareholder", said a relative of the folder. A structured project must be presented at the meeting of the Aventis Supervisory Board, on 2 April.
A report on Plavix
Igor Landau Group continues, moreover, to adopt a posture of very hostile facade to Sanofi-Synthelabo. He held Friday, with the financial analysts, a conference call on Plavix, a drug of the Group of Jean-François Dehecq, potentially threatened by competition from generics. According to the findings of the report described as "independent" by Aventis, which was presented by counsel U.S. and sent to the authority of des marchés financiers (AMF) and the Securities and Exchange Commission (SEC), generic manufacturers have raised "serious validity issues" of the patent which cannot be "readily excluded."
Aventis, which is increasingly more isolated, with the likely withdrawal of Novartis, and the attitude of the French Government, perhaps thus seeks ways to sustain the pressure on Sanofi-Synthelabo for a rehabilitation of its offer. If it "significantly" revalorisait the proposed price, the Franco-German group could agree to discuss with him, were also moving some relatives of Igor Landau, Friday.
The intervention of the French Government in this case is in any case not to the taste of everyone. The Association for the defence of minority shareholders (Adam) seized Friday the AMF to make it comply with "the free play of outbid." Government statements would, in her view, barrier to the market mechanism, and it would result in harm to the shareholders of Aventis. In addition, Adam President Colette Neuville, assured that it would not hesitate "to address in a later phase to Mario Monti (the European Commissioner for competition, Editor's note) so there is no impediment to competition". Precisely, the European Commission said Friday that it would have its word to say about the intervention of the French State to counter the Novartis offer (see box opposite).
What convert to worship Tesco last skepticsAnd the evidence that classical and sexy mixOf course this reduction is partly suffered1 billion dollars below analysts forecastsFind the articles in the series of summer onThe PS program plans to remove habitat unworthyOne a stroller must remain within VHF reachWe have applied the idea throughout the systemIt ceased to argue so far to move up a gear1 billion euros but also in transport energy space
